SAN DIEGO, Sept. 30, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has obtained the required long-term clinical exposure data from its Phase 3 open label safety study (Study 802) of Zohydro™ (hydrocodone bitartrate) extended-release capsules. The safety database of at least 300 patients on therapy with Zohydro for six months and at least 100 patients on therapy with Zohydro for one year is a requisite component of the 505(b)(2) New Drug Application (NDA) for Zohydro to the U.S. Food and Drug Administration (FDA), which remains on track for submission in early 2012.
